Dr. Raphael Schiffmann

Neurology
6080 N Central Expy, Ste 100, 
Dallas, TX 
Offers Telehealth
46 Years of Experience
6080 N Central Expy, Ste 100, 
Dallas, TX 
OverviewInsuranceLocationsClinical Research

Overview

Raphael Schiffmann is a Neurologist in Dallas, Texas. Dr. Schiffmann has been practicing medicine for over 46 years and is rated as an Experienced provider by MediFind in the treatment of Syndactyly. His top areas of expertise are Gaucher Disease Type 3, Fabry Disease, Gaucher Disease, and Leukodystrophy.

His clinical research consists of co-authoring 133 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Liege, 1980.0
Residency
Pediatrics, Shaare Zedek Medical Center
Specialties
Neurology
Licenses
Neurology with Special Qualifications in Neurology in TX
Board Certifications
American Board Of Psychiatry And Neurology
Fellowships
Pediatric Neurology, Boston City Hospital
Pediatric Neurology, Tufts New England Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Texas Neurology, P.A.
6080 N Central Expy, Ste 100, Dallas, TX 75206

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Variants
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Variants
Enrollment Status: Completed
Publish Date: November 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy
An Open-Label Clinical Trial of Replagal® Enzyme Replacement Therapy in Children With Fabry Disease Who Are Naive to Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Biological
Study Phase: Phase 2
An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients With Fabry Disease.
An Open-label Treatment Protocol to Evaluate the Safety of Replagal Treatment in Patients With Fabry Disease.
Enrollment Status: No_longer_available
Publish Date: May 24, 2021
Intervention Type: Biological
The Etiology, Pathogenesis, and Natural History of the Leukodystrophies
The Etiology, Pathogenesis, and Natural History of the Leukodystrophies
Enrollment Status: Completed
Publish Date: March 22, 2019
View 5 Less Clinical Trials

132 Total Publications

Expanded View of the Pathophysiology of Fabry Disease.
Expanded View of the Pathophysiology of Fabry Disease.
Journal: Nephron
Published: May 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schiffmann's expertise for a condition
ConditionClose
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile